Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK.

J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30.

PMID:
29381435
2.

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, Baz R, Mau-Sorensen M, Berdeja JG, Savona M, Savoie L, Trudel S, Areethamsirikul N, Unger TJ, Rashal T, Hanke T, Kauffman M, Shacham S, Reece D.

Blood. 2018 Feb 22;131(8):855-863. doi: 10.1182/blood-2017-08-797886. Epub 2017 Dec 4.

PMID:
29203585
3.

Virulence characteristics and molecular relatedness of methicillin resistant Staphylococcus aureus harboring different staphylococcal cassette chromosome mec.

El-Baz R, Rizk DE, Barwa R, Hassan R.

Microb Pathog. 2017 Dec;113:385-395. doi: 10.1016/j.micpath.2017.11.021. Epub 2017 Nov 15.

PMID:
29155125
4.

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

Brayer J, Baz R.

Ther Adv Hematol. 2017 Jul;8(7):209-220. doi: 10.1177/2040620717710171. Epub 2017 Jun 28. Review.

5.

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R.

Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.

6.

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M.

Blood. 2017 Jun 15;129(24):3175-3183. doi: 10.1182/blood-2016-11-750174. Epub 2017 May 3.

PMID:
28468797
7.

Genetic polymorphisms of IL-23R (rs7517847) and LEP (rs7799039) among Egyptian patients with hepatocellular carcinoma.

Amer T, El-Baz R, Mokhtar AR, El-Shaer S, Elshazli R, Settin A.

Arch Physiol Biochem. 2017 Dec;123(5):279-285. doi: 10.1080/13813455.2017.1320680. Epub 2017 Apr 28.

PMID:
28452232
8.

An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma.

Silva A, Silva MC, Sudalagunta P, Distler A, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt C, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby R, Gillies R, Sontag E, Meads MB, Shain KH.

Cancer Res. 2017 Jun 15;77(12):3336-3351. doi: 10.1158/0008-5472.CAN-17-0502. Epub 2017 Apr 11.

PMID:
28400475
9.

Genetic polymorphisms of NFκB1-94ins/delATTG and NFκBIA-881A/G genes in Egyptian patients with colorectal cancer.

Youssef MR, Attia ZI, El-Baz RA, Roshdy S, Settin A.

Fam Cancer. 2017 Oct;16(4):517-524. doi: 10.1007/s10689-017-9992-y.

PMID:
28389768
10.

Waldenström Macroglobulinemia: Review of Pathogenesis and Management.

Yun S, Johnson AC, Okolo ON, Arnold SJ, McBride A, Zhang L, Baz RC, Anwer F.

Clin Lymphoma Myeloma Leuk. 2017 May;17(5):252-262. doi: 10.1016/j.clml.2017.02.028. Epub 2017 Mar 7. Review.

PMID:
28366781
11.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R.

Blood. 2017 Jun 15;129(24):3165-3174. doi: 10.1182/blood-2016-11-750158. Epub 2017 Mar 23.

PMID:
28336527
12.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582
13.

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.

Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM.

J Hematol Oncol. 2016 Aug 24;9(1):73. doi: 10.1186/s13045-016-0304-z.

14.

Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.

Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH.

Leuk Lymphoma. 2017 Mar;58(3):560-568. doi: 10.1080/10428194.2016.1207763. Epub 2016 Jul 18.

PMID:
27424609
15.

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.

Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A.

Leuk Lymphoma. 2016 Dec;57(12):2833-2838. Epub 2016 Jun 7.

PMID:
27267105
16.

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.

Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S.

Blood. 2016 May 26;127(21):2561-8. doi: 10.1182/blood-2015-11-682518. Epub 2016 Mar 1.

17.

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.

Baz RC, Zonder JA, Gasparetto C, Reu FJ, Strout V.

Oncol Ther. 2016;4(2):287-301. doi: 10.1007/s40487-016-0034-y. Epub 2016 Nov 2.

18.

Clinical presentation of a patient with cutis laxa with systemic involvement: a case report.

Tofolean DE, Mazilu L, Stăniceanu F, Mocanu L, Suceveanu AI, Baz RO, Parepa RI, Suceveanu AP, Bondari S, Bondari D, Voinea F.

Rom J Morphol Embryol. 2015;56(3):1205-10.

19.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.

Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7.

20.

Response to letter, 'immortal time bias in retrospective analysis'.

Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R.

Blood Cancer J. 2015 Jul 31;5:e327. doi: 10.1038/bcj.2015.55. No abstract available.

21.

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.

Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC.

Cancer. 2015 Oct 15;121(20):3622-30. doi: 10.1002/cncr.29533. Epub 2015 Jul 6.

22.

Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response.

Hassoun Y, Kharfan-Dabaja MA, Baz R.

Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):138-9. doi: 10.1016/j.hemonc.2015.01.002. Epub 2015 Feb 23. No abstract available.

23.

Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.

Baz R, Lin HM, Hui AM, Harvey RD, Colson K, Gallop K, Swinburn P, Laubach J, Berg D, Richardson P.

Support Care Cancer. 2015 Sep;23(9):2789-97. doi: 10.1007/s00520-015-2644-6. Epub 2015 Feb 24.

PMID:
25708126
24.

An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.

Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M.

Eur J Haematol. 2015 Nov;95(5):426-35. doi: 10.1111/ejh.12509. Epub 2015 Mar 12.

25.

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R.

Blood Cancer J. 2014 Nov 7;4:e257. doi: 10.1038/bcj.2014.77.

26.

Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S.

Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23.

27.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S.

Blood. 2014 Aug 14;124(7):1038-46. doi: 10.1182/blood-2014-01-548826. Epub 2014 Jun 11.

28.

Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients.

Remily-Wood ER, Benson K, Baz RC, Chen YA, Hussein M, Hartley-Brown MA, Sprung RW, Perez B, Liu RZ, Yoder SJ, Teer JK, Eschrich SA, Koomen JM.

Proteomics Clin Appl. 2014 Oct;8(9-10):783-95. doi: 10.1002/prca.201300077. Epub 2014 Sep 15.

29.

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM.

Semin Cancer Biol. 2014 Aug;27:62-73. doi: 10.1016/j.semcancer.2014.03.001. Epub 2014 Mar 12. Review.

30.

Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.

Settin A, Abdalla AF, Al-Hussaini AS, El-Baz R, Galal A.

Indian J Gastroenterol. 2014 Jul;33(4):330-5. doi: 10.1007/s12664-014-0450-6. Epub 2014 Mar 8.

PMID:
24610583
31.

Association of ACE and MTHFR genetic polymorphisms with type 2 diabetes mellitus: Susceptibility and complications.

Settin A, El-Baz R, Ismaeel A, Tolba W, Allah WA.

J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):838-43. doi: 10.1177/1470320313516172. Epub 2014 Jan 22.

PMID:
24452036
32.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC.

Blood. 2014 Mar 20;123(12):1826-32. doi: 10.1182/blood-2013-11-538835. Epub 2014 Jan 13. Erratum in: Blood. 2014 May 15;123(20):3208-9.

33.

[Infrequent complication of diagnostic colonoscopy].

Lus Pérez S, Gotti R, Maceratini J, Baz R.

Acta Gastroenterol Latinoam. 2014;44(4):283, 348. Spanish. No abstract available.

PMID:
26753376
34.

A preclinical assay for chemosensitivity in multiple myeloma.

Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS.

Cancer Res. 2014 Jan 1;74(1):56-67. doi: 10.1158/0008-5472.CAN-13-2397. Epub 2013 Dec 5.

35.

Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.

Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K, Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R.

Am J Hematol. 2014 Apr;89(4):349-54. doi: 10.1002/ajh.23639. Epub 2014 Feb 24.

36.

Longitudinal assessment in COPD patients: multidimensional variability and outcomes.

Casanova C, Aguirre-Jaíme A, de Torres JP, Pinto-Plata V, Baz R, Marin JM, Divo M, Cordoba E, Basaldua S, Cote C, Celli BR.

Eur Respir J. 2014 Mar;43(3):745-53. doi: 10.1183/09031936.00096913. Epub 2013 Sep 26.

37.

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.

Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Oliver EF, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M.

Am J Hematol. 2014 Jan;89(1):62-7. doi: 10.1002/ajh.23587.

38.

Optimizing the indication for breast-conservative surgery (BCS) in patients with locally-advanced breast cancer.

Mazilu L, Suceveanu AI, Tomescu D, Ciufu N, Baz R, Suceveanu AP, Parepa IR, Tofolean DE, Voinea F.

Chirurgia (Bucur). 2013 Jul-Aug;108(4):478-81.

39.

Sequence of novel agents in multiple myeloma: an instrumental variable analysis.

Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B.

Leuk Res. 2013 Sep;37(9):1077-82. doi: 10.1016/j.leukres.2013.06.005. Epub 2013 Jun 25.

PMID:
23809054
40.

Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.

Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M.

Bone Marrow Transplant. 2013 Sep;48(9):1179-84. doi: 10.1038/bmt.2013.37. Epub 2013 Apr 1.

41.

Tumor necrosis factor-α gene polymorphism relationship to seminal variables in infertile men.

Zalata A, Atwa A, El-Naser Badawy A, Aziz A, El-Baz R, Elhanbly S, Mostafa T.

Urology. 2013 May;81(5):962-6. doi: 10.1016/j.urology.2013.01.026. Epub 2013 Mar 5.

PMID:
23465534
42.

Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.

Nishihori T, Abu Kar SM, Baz R, Alsina M, Harousseau JL, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1144-51. doi: 10.1016/j.bbmt.2013.02.003. Epub 2013 Feb 13. Review.

43.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC.

Blood. 2013 Mar 14;121(11):1961-7. doi: 10.1182/blood-2012-08-450742. Epub 2012 Dec 14.

44.

Stemness of B-cell progenitors in multiple myeloma bone marrow.

Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE.

Clin Cancer Res. 2012 Nov 15;18(22):6155-68. doi: 10.1158/1078-0432.CCR-12-0531. Epub 2012 Sep 17.

45.

Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.

Pinto-Plata V, Casanova C, Müllerova H, de Torres JP, Corado H, Varo N, Cordoba E, Zeineldine S, Paz H, Baz R, Divo M, Cortopassi F, Celli BR.

Respir Res. 2012 Aug 20;13:71. doi: 10.1186/1465-9921-13-71.

46.

Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial.

Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D.

J Clin Oncol. 2012 Jul 10;30(20):2516-21. doi: 10.1200/JCO.2011.39.5186. Epub 2012 May 21.

47.

MTHFR C677T, A1298C and ACE I/D polymorphisms as risk factors for diabetic nephropathy among type 2 diabetic patients.

El-Baz R, Settin A, Ismaeel A, Khaleel AA, Abbas T, Tolba W, Abd Allah W, Sobh MA.

J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):472-7. doi: 10.1177/1470320312444651. Epub 2012 May 3.

PMID:
22554825
48.

Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.

Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M.

Br J Haematol. 2012 Jun;157(5):553-63. doi: 10.1111/j.1365-2141.2012.09099.x. Epub 2012 Mar 26.

49.

Who needs admission among infants with acute otitis media?

Bitar MA, Baz R, Sabra O.

J Paediatr Child Health. 2012 May;48(5):435-8. doi: 10.1111/j.1440-1754.2011.02249.x. Epub 2011 Nov 23.

PMID:
22107109
50.

A Novel High-Throughput Screening Assay to Identify Inhibitors of HIV-1 gp120 Protein Interaction with DC-SIGN.

Tran TH, El Baz R, Cuconati A, Arthos J, Jain P, Khan ZK.

J Antivir Antiretrovir. 2011 Oct 17;3:49-54.

Supplemental Content

Support Center